Amount of additional milestone payments.

No definition available.

Name:	casi_AdditionalMilestonePayments
Namespace Prefix:	casi_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Accrued milestone payment under license agreement.

+ References

No definition available.

+ Details

Name:	casi_LicenseAgreementAccruedMilestonePayment
Namespace Prefix:	casi_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Contingent milestone payment under license agreement.

+ References

No definition available.

+ Details

Name:	casi_LicenseAgreementContingentMilestonePayment
Namespace Prefix:	casi_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of milestone payment under license agreement.

+ References

No definition available.

+ Details

Name:	casi_LicenseAgreementMilestonePayment
Namespace Prefix:	casi_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The additional period after the product launch, for which the company has non-royalty exclusive distribution rights, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	casi_NonRoyaltyExclusiveDistributionAdditionalPeriod
Namespace Prefix:	casi_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The period after the product launch, for which the company has non-royalty exclusive distribution rights, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	casi_NonRoyaltyExclusiveDistributionPeriod
Namespace Prefix:	casi_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The period considered for determination of supply costs in connection with the non-royalty exclusive distribution, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	casi_NonRoyaltyExclusiveDistributionSupplyCostDeterminationPeriodConsidered
Namespace Prefix:	casi_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of installments for upfront payment.

+ References

No definition available.

+ Details

Name:	casi_NumberOfInstallmentsForUpfrontPayment
Namespace Prefix:	casi_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

The potential milestone and royalty payment.

+ References

No definition available.

+ Details

Name:	casi_PotentialMilestonePaymentAndRoyalty
Namespace Prefix:	casi_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of upfront payment.

+ References

No definition available.

+ Details

Name:	casi_UpfrontPayment
Namespace Prefix:	casi_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275

+ Details

Name:	us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Indicates line item in statement of income or comprehensive income that includes writeoff for research and development asset acquired in transaction other than business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275

+ Details

Name:	us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
Namespace Prefix:	us-gaap_
Data Type:	enum2:enumerationSetItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.

+ References

No definition available.

+ Details

Name:	us-gaap_ResearchAndDevelopmentInProcess
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	casi_InvestmentsContractCounterpartyAxis=casi_GuokangPharmaceuticalsCoLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	casi_InvestmentsContractCounterpartyAxis=casi_BeijingTianshiTongdaPharmaceuticalsTechnologyCo.LtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	casi_InvestmentsContractCounterpartyAxis=casi_PharmathenGlobalBvMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	casi_InvestmentsContractCounterpartyAxis=casi_BlackBeltTherapeuticsLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	casi_InvestmentsContractCounterpartyAxis=casi_CleaveTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	casi_InvestmentsContractCounterpartyAxis=casi_JuventasCellTherapyLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	casi_InvestmentsContractCounterpartyAxis=casi_BioinventInternationalAbMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	casi_InvestmentsContractCounterpartyAxis=casi_ReimserPharmaGmbhMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

License and Distribution Agreements (Details) ¥ in Millions		1 Months Ended											3 Months Ended			6 Months Ended		12 Months Ended
License and Distribution Agreements (Details) ¥ in Millions	Oct. 29, 2019	May 31, 2022 USD ($) installment	Aug. 31, 2021 USD ($)	Aug. 31, 2021 EUR (€)	Jun. 30, 2021 USD ($)	Mar. 31, 2021 USD ($)	Nov. 30, 2020 USD ($)	Sep. 30, 2020 USD ($)	Sep. 30, 2020 CNY (¥)	Apr. 30, 2019 USD ($)	Apr. 30, 2019 EUR (€)	Mar. 31, 2019	Jun. 30, 2022 USD ($)	Mar. 31, 2022	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2020 EUR (€)	Dec. 31, 2019 EUR (€)	Aug. 31, 2021 EUR (€)
License and Distribution Agreements
Research and Development Asset Acquired Other than through Business Combination, Writeoff, Statement of Income or Comprehensive Income [Extensible Enumeration]																		Acquired in-process research and development
Acquired in-process research and development													$ 0		$ 1,055,000	$ 0	$ 6,555,000
China Resources Guokang Pharmaceuticals Co., Ltd
License and Distribution Agreements
Non Royalty Exclusive Distribution Period												3 years
Non royalty exclusive distribution additional period														2 years
Beijing Tianshi Tongda Pharmaceuticals Technology Co., Ltd
License and Distribution Agreements
Upfront payment		$ 10,000,000
Number of installments for upfront payment \| installment		2
Pharmathen Global BV
License and Distribution Agreements
Upfront payment \| €																					€ 1,000,000
Non Royalty Exclusive Distribution Period	10 years
Additional milestone payments paid																			$ 1,700,000	€ 1,500,000
Non-royalty exclusive distribution period at agreed cost	3 years
Pharmathen Global BV \| Maximum
License and Distribution Agreements
Additional milestone payments paid \| €																				€ 2,000,000
Black Belt Therapeutics Ltd
License and Distribution Agreements
Upfront payment										$ 5,700,000	€ 5,000,000										€ 5,000,000
Milestone payment			$ 305,000	€ 250,000	$ 750,000
Accrued milestone payment			$ 305,000																			€ 250,000
In-process research and development expensed																		$ 1,100,000
Potential milestones and royalties of up to										$ 46,300,000
Cleave Therapeutics, Inc
License and Distribution Agreements
Upfront payment						$ 5,500,000
Acquired in-process research and development																		$ 5,500,000
Cleave Therapeutics, Inc \| Maximum
License and Distribution Agreements
Milestone payment						$ 74,000,000
Juventas Cell Therapy Ltd.
License and Distribution Agreements
Milestone payment								$ 10,000,000	¥ 70
BioInvent International AB
License and Distribution Agreements
Upfront payment							$ 5,900,000
Acquired in-process research and development																			$ 5,900,000
BioInvent International AB \| Maximum
License and Distribution Agreements
Potential milestones and royalties of up to							$ 83,000,000
Riemser Pharma GmbH
License and Distribution Agreements
Contingent milestone payment													$ 0			$ 0